JPH0248547B2 - - Google Patents
Info
- Publication number
- JPH0248547B2 JPH0248547B2 JP55165956A JP16595680A JPH0248547B2 JP H0248547 B2 JPH0248547 B2 JP H0248547B2 JP 55165956 A JP55165956 A JP 55165956A JP 16595680 A JP16595680 A JP 16595680A JP H0248547 B2 JPH0248547 B2 JP H0248547B2
- Authority
- JP
- Japan
- Prior art keywords
- acetone
- amsa
- solution
- lactate
- acridinylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 132
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims description 68
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 37
- 239000012453 solvate Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 13
- CIFNWWSBOFZXJI-UHFFFAOYSA-N 2-hydroxypropanoic acid;propan-2-one Chemical compound CC(C)=O.CC(O)C(O)=O CIFNWWSBOFZXJI-UHFFFAOYSA-N 0.000 claims description 11
- 239000004310 lactic acid Substances 0.000 claims description 9
- 235000014655 lactic acid Nutrition 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 claims description 4
- 150000003893 lactate salts Chemical class 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 2
- 238000011109 contamination Methods 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 62
- 150000003839 salts Chemical class 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 239000013078 crystal Substances 0.000 description 27
- 229960000448 lactic acid Drugs 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- 239000011521 glass Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 238000001990 intravenous administration Methods 0.000 description 12
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 238000002425 crystallisation Methods 0.000 description 10
- 230000008025 crystallization Effects 0.000 description 10
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000008223 sterile water Substances 0.000 description 8
- JVTAAEKCZFNVCJ-REOHCLBHSA-M (S)-lactate Chemical compound C[C@H](O)C([O-])=O JVTAAEKCZFNVCJ-REOHCLBHSA-M 0.000 description 7
- 238000000862 absorption spectrum Methods 0.000 description 6
- 229910001220 stainless steel Inorganic materials 0.000 description 6
- 239000010935 stainless steel Substances 0.000 description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000000921 elemental analysis Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000001291 vacuum drying Methods 0.000 description 5
- OZZQHCBFUVFZGT-UHFFFAOYSA-N 2-(2-hydroxypropanoyloxy)propanoic acid Chemical compound CC(O)C(=O)OC(C)C(O)=O OZZQHCBFUVFZGT-UHFFFAOYSA-N 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000008135 aqueous vehicle Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 238000002834 transmittance Methods 0.000 description 3
- 238000003828 vacuum filtration Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940058352 levulinate Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MNKRTDOUBUSQHX-UHFFFAOYSA-N 2,4-dihydroxy-2-methyl-3-oxopentanoic acid Chemical compound CC(O)C(=O)C(C)(O)C(O)=O MNKRTDOUBUSQHX-UHFFFAOYSA-N 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 150000001251 acridines Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000006207 intravenous dosage form Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- -1 lactate acetonate salts Chemical class 0.000 description 1
- 229940106852 lactic acid 100 mg/ml Drugs 0.000 description 1
- WDISRLXRMMTXEV-UHFFFAOYSA-N n-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide;hydron;chloride Chemical compound Cl.COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 WDISRLXRMMTXEV-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008054 sulfonate salts Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9916379A | 1979-11-30 | 1979-11-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5687566A JPS5687566A (en) | 1981-07-16 |
| JPH0248547B2 true JPH0248547B2 (ko) | 1990-10-25 |
Family
ID=22273241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP16595680A Granted JPS5687566A (en) | 1979-11-30 | 1980-11-27 | Anticancerous composition |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPS5687566A (ko) |
| BE (1) | BE886413A (ko) |
| ZA (1) | ZA807469B (ko) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA811304B (en) * | 1980-03-11 | 1982-06-30 | Warner Lambert Co | Pharmaceutical salts of 4'-(9-acridinylamino)methanesulfon-m-anisidide |
-
1980
- 1980-11-27 JP JP16595680A patent/JPS5687566A/ja active Granted
- 1980-11-28 ZA ZA00807469A patent/ZA807469B/xx unknown
- 1980-11-28 BE BE0/202984A patent/BE886413A/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5687566A (en) | 1981-07-16 |
| ZA807469B (en) | 1981-11-25 |
| BE886413A (fr) | 1981-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR880002087B1 (ko) | 항균성 나프티리딘 또는 퀴놀린 화합물의 염 및 그의 제조방법 | |
| JPH055810B2 (ko) | ||
| JP2021523880A (ja) | ジヒドロピリミジン化合物の固体形態及びその調製方法及びその使用 | |
| CA1160571A (en) | Antitumor compositions | |
| JPS5925377A (ja) | メトロニダゾ−ルとｎ，ｎ−ジメチルグリシンとのエステルおよびその酸付加湿 | |
| KR840000702B1 (ko) | 빈카민 사카리네이트의 제조방법 | |
| JPH0248547B2 (ko) | ||
| EP0042553B1 (en) | Antitumor compositions | |
| US4335244A (en) | Monolactate salts of 4'-(9-acridinylamino)methanesulfon-m-anisidide | |
| SU1122225A3 (ru) | Способ получени кристаллической водорастворимой негигроскопичной этилендиаминовой,моноэтаноламиновой или диэтаноламиновой соли @ -(2-пиридил)-2-метил-4-окси-2 @ -1,2-бензтиазин-3-карбоксамид-1,1-диоксида | |
| UA52661C2 (uk) | Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти | |
| CA1252103A (en) | Crystalline gluconate salt of 4'-(9-acridinylamino)- methanesulfo-m-anisidide | |
| CA1159369A (en) | Crystalline mono dl-lactate hemiacetonate of 4-(9- acridinylamino) methanesulfo-m-anisidide | |
| ES2969594T3 (es) | Complejo de 7-desacetilforskolina y PVP | |
| CA1191090A (en) | Antitumor compositions | |
| JPH0315632B2 (ko) | ||
| CA2039120C (fr) | Complexes de l'acide tiaprofenique ou de ses esters insolubles ou partiellement solubles avec les cyclodextrines ou leurs derives | |
| JPH032862B2 (ko) | ||
| CA1159368A (en) | Antitumor compositions |